PL2710005T3 - Inhibitory kinazy tyrozynowej - Google Patents
Inhibitory kinazy tyrozynowejInfo
- Publication number
- PL2710005T3 PL2710005T3 PL12722662T PL12722662T PL2710005T3 PL 2710005 T3 PL2710005 T3 PL 2710005T3 PL 12722662 T PL12722662 T PL 12722662T PL 12722662 T PL12722662 T PL 12722662T PL 2710005 T3 PL2710005 T3 PL 2710005T3
- Authority
- PL
- Poland
- Prior art keywords
- tyrosine kinase
- kinase inhibitors
- inhibitors
- tyrosine
- kinase
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161486944P | 2011-05-17 | 2011-05-17 | |
| US201161514892P | 2011-08-03 | 2011-08-03 | |
| US201161556336P | 2011-11-07 | 2011-11-07 | |
| US201261618152P | 2012-03-30 | 2012-03-30 | |
| EP12722662.9A EP2710005B1 (en) | 2011-05-17 | 2012-05-16 | Tyrosine kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2710005T3 true PL2710005T3 (pl) | 2017-07-31 |
Family
ID=46147109
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL12722662T PL2710005T3 (pl) | 2011-05-17 | 2012-05-16 | Inhibitory kinazy tyrozynowej |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US8962831B2 (pl) |
| EP (1) | EP2710005B1 (pl) |
| JP (1) | JP5974084B2 (pl) |
| KR (1) | KR102027598B1 (pl) |
| CN (1) | CN103534258B (pl) |
| AU (3) | AU2012255860C1 (pl) |
| CA (1) | CA2836410C (pl) |
| EA (1) | EA025496B1 (pl) |
| ES (1) | ES2604191T3 (pl) |
| HR (1) | HRP20170017T1 (pl) |
| HU (1) | HUE033019T2 (pl) |
| MX (1) | MX347040B (pl) |
| PL (1) | PL2710005T3 (pl) |
| PT (1) | PT2710005T (pl) |
| SI (1) | SI2710005T1 (pl) |
| WO (1) | WO2012158764A1 (pl) |
Families Citing this family (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8809273B2 (en) | 2007-03-28 | 2014-08-19 | Pharmacyclics, Inc. | Inhibitors of Bruton's tyrosine kinase |
| AU2009270856B2 (en) | 2008-07-16 | 2013-07-25 | Pharmacyclics Llc | Inhibitors of Bruton's tyrosine kinase for the treatment of solid tumors |
| MX342405B (es) | 2010-06-03 | 2016-09-28 | Pharmacyclics Inc | El uso de inhibidores de la tirosina quinasa de bruton (btk). |
| US8962831B2 (en) | 2011-05-17 | 2015-02-24 | Principia Biopharma Inc. | Tyrosine kinase inhibitors |
| US9580427B2 (en) | 2011-05-17 | 2017-02-28 | The Regents Of The University Of California | Kinase inhibitors |
| WO2012158795A1 (en) | 2011-05-17 | 2012-11-22 | Principia Biopharma Inc. | Pyrazolopyrimidine derivatives as tyrosine kinase inhibitors |
| BR112014000653A2 (pt) | 2011-07-13 | 2017-02-14 | Pharmacyclics Inc | inibidores de tirosina quinase de bruton |
| US8377946B1 (en) | 2011-12-30 | 2013-02-19 | Pharmacyclics, Inc. | Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors |
| KR20150015021A (ko) | 2012-06-04 | 2015-02-09 | 파마시클릭스, 인코포레이티드 | 브루톤 타이로신 키나아제 저해제의 결정 형태 |
| MX368112B (es) * | 2012-06-18 | 2019-09-18 | Principia Biopharma Inc | Pirrolo- o pirazolopirimidinas covalentes reversibles utiles para el tratamiento del cancer y de enfermedades autoinmunitarias. |
| AU2013293087B2 (en) | 2012-07-24 | 2017-08-31 | Pharmacyclics Llc | Mutations associated with resistance to inhibitors of Bruton's tyrosine kinase (BTK) |
| EP2890691B1 (en) | 2012-08-31 | 2018-04-25 | Principia Biopharma Inc. | Benzimidazole derivatives as itk inhibitors |
| WO2014039899A1 (en) | 2012-09-10 | 2014-03-13 | Principia Biopharma Inc. | Pyrazolopyrimidine compounds as kinase inhibitors |
| PE20151495A1 (es) | 2012-11-15 | 2015-10-23 | Pharmacyclics Inc | Compuestos de pirrolopirimidina como inhibidores de quinasas |
| US8957080B2 (en) | 2013-04-09 | 2015-02-17 | Principia Biopharma Inc. | Tyrosine kinase inhibitors |
| DK2989106T3 (en) | 2013-04-25 | 2017-03-20 | Beigene Ltd | CONDENSED HETEROCYCLIC COMPOUNDS AS PROTEINKINASE INHIBITORS |
| GB201309085D0 (en) | 2013-05-20 | 2013-07-03 | Redx Pharma Ltd | Compounds |
| EP2999702A4 (en) * | 2013-05-21 | 2017-01-11 | Jiangsu Medolution Ltd. | Substituted pyrazolopyrimidines as kinases inhibitors |
| ES2709509T3 (es) | 2013-08-12 | 2019-04-16 | Pharmacyclics Llc | Procedimientos para el tratamiento de cáncer amplificado por HER2 |
| HUE060420T2 (hu) | 2013-09-13 | 2023-02-28 | Beigene Switzerland Gmbh | Anti-PD1 antitestek, valamint terapeutikumként és diagnosztikumként történõ alkalmazásuk |
| MA38961A1 (fr) | 2013-09-30 | 2018-05-31 | Pharmacyclics Llc | Composés 3-phenyl-1h-pyrazolo[3,4-d]pyrimidin-4-ylamine substitués inhibiteurs de la tyrosine kinase de bruton utilisés pour traiter par exemple les maladies auto-immunes, respiratoires et inflammatoires, cancer, mastocytose et osteoporose |
| BR112016018948B1 (pt) * | 2014-02-21 | 2023-01-17 | Principia Biopharma Inc | Uso de composto ou sal farmaceuticamente aceitável, ácido sulfônico ou sal de ácido carboxílico de composto, forma amorfa de sal farmaceuticamente aceitável de composto, composição farmacêutica e respectivo uso |
| WO2015143400A1 (en) | 2014-03-20 | 2015-09-24 | Pharmacyclics, Inc. | Phospholipase c gamma 2 and resistance associated mutations |
| CN105017256A (zh) * | 2014-04-29 | 2015-11-04 | 浙江导明医药科技有限公司 | 多氟化合物作为布鲁顿酪氨酸激酶抑制剂 |
| GB201410430D0 (en) | 2014-06-11 | 2014-07-23 | Redx Pharma Ltd | Compounds |
| EP3160505A4 (en) | 2014-07-03 | 2018-01-24 | BeiGene, Ltd. | Anti-pd-l1 antibodies and their use as therapeutics and diagnostics |
| CA2959602A1 (en) | 2014-08-01 | 2016-02-04 | Pharmacyclics Llc | Inhibitors of bruton's tyrosine kinase |
| WO2016022942A1 (en) | 2014-08-07 | 2016-02-11 | Pharmacyclics Llc | Novel formulations of a bruton's tyrosine kinase inhibitor |
| CN105399756B (zh) * | 2014-09-05 | 2019-06-25 | 广东东阳光药业有限公司 | Btk抑制剂及其用途 |
| MA41197B1 (fr) | 2014-12-18 | 2021-01-29 | Principia Biopharma Inc | Traitement de le pemphigus |
| CN105820168B (zh) * | 2015-01-09 | 2018-12-04 | 上海医药工业研究院 | 一种依鲁替尼中间体的制备方法 |
| CN104557945B (zh) * | 2015-01-27 | 2017-08-04 | 安润医药科技（苏州）有限公司 | 依鲁替尼合成方法 |
| RU2017133990A (ru) | 2015-03-03 | 2019-04-05 | Фармасайкликс Элэлси | Фармацевтические лекарственные формы ингибитора тирозинкиназы брутона |
| US9717745B2 (en) | 2015-03-19 | 2017-08-01 | Zhejiang DTRM Biopharma Co. Ltd. | Pharmaceutical compositions and their use for treatment of cancer and autoimmune diseases |
| CN106146508A (zh) * | 2015-03-19 | 2016-11-23 | 浙江导明医药科技有限公司 | 优化的联合用药及其治疗癌症和自身免疫疾病的用途 |
| CN106146512B (zh) * | 2015-04-09 | 2018-07-17 | 北京睿创康泰医药研究院有限公司 | 依鲁替尼的制备方法 |
| CN104844580B (zh) * | 2015-04-17 | 2017-10-20 | 中国药科大学 | 嘧啶类化合物、其制备方法及医药用途 |
| CN106188062A (zh) * | 2015-05-08 | 2016-12-07 | 苏州鹏旭医药科技有限公司 | 依鲁替尼的制备方法、依鲁替尼的中间体及中间体的制备方法 |
| KR102552653B1 (ko) * | 2015-06-03 | 2023-07-07 | 프린시피아 바이오파마, 인코퍼레이티드 | 티로신 키나제 억제제 |
| US20180305350A1 (en) * | 2015-06-24 | 2018-10-25 | Principia Biopharma Inc. | Tyrosine kinase inhibitors |
| WO2017027883A1 (en) * | 2015-08-13 | 2017-02-16 | San Diego State University Research Foundation | Atropisomerism for increased kinase inhibitor selectivity |
| WO2017038838A1 (ja) * | 2015-09-01 | 2017-03-09 | 大鵬薬品工業株式会社 | 新規なピラゾロ［３，４－ｄ］ピリミジン化合物又はその塩 |
| EA201890730A1 (ru) | 2015-09-16 | 2018-10-31 | Локсо Онколоджи, Инк. | Производные пиразолопиримидина в качестве ингибиторов btk для лечения злокачественного новообразования |
| SG10202012498TA (en) | 2015-12-16 | 2021-01-28 | Loxo Oncology Inc | Compounds useful as kinase inhibitors |
| CN107021963A (zh) | 2016-01-29 | 2017-08-08 | 北京诺诚健华医药科技有限公司 | 吡唑稠环类衍生物、其制备方法及其在治疗癌症、炎症和免疫性疾病上的应用 |
| UA123785C2 (uk) | 2016-03-28 | 2021-06-02 | Інсайт Корпорейшн | Сполуки піролотриазину як інгібітори tam |
| WO2017198049A1 (zh) * | 2016-05-16 | 2017-11-23 | 浙江予川医药科技有限公司 | 作为btk抑制剂的吡唑并嘧啶衍生物及其制备方法和药物组合物 |
| MA45547A (fr) | 2016-06-29 | 2019-05-08 | Principia Biopharma Inc | Formulations à libération modifiée à base de 2-[3-[4-amino-3-(2-fluoro-4-phénoxy-phényl)pyrazolo[3,4-d]pyrimidine-1-yl]pipéridine-1-carbonyl]-4-méthyl-4-[4-(oxétane-3-yl)pipérazine-1-yl]pent-2-ènenitrile |
| JP6993056B2 (ja) | 2016-07-05 | 2022-02-15 | ベイジーン リミテッド | 癌治療のためのｐｄ－１アンタゴニスト及びｒａｆ阻害剤の組合せ |
| CN116478166A (zh) | 2016-08-16 | 2023-07-25 | 百济神州(苏州)生物科技有限公司 | 一种化合物的晶型、其制备和用途 |
| AU2017313085A1 (en) | 2016-08-19 | 2019-03-14 | Beigene Switzerland Gmbh | Use of a combination comprising a Btk inhibitor for treating cancers |
| MA46285A (fr) | 2016-09-19 | 2019-07-31 | Mei Pharma Inc | Polythérapie |
| EP3573989A4 (en) | 2017-01-25 | 2020-11-18 | Beigene, Ltd. | CRYSTALLINE FORMS OF (S) -7- (1- (BUT-2-YNOYL) -PIPERIDINE-4-YL) -2- (4-PHENOXYPHENYL) -4,5,6,7-TETRAHYDROPYRAZOLO [1,5-A ] PYRIMIDINE-3-CARBOXAMIDE, MANUFACTURING AND USES THEREOF |
| US11597768B2 (en) | 2017-06-26 | 2023-03-07 | Beigene, Ltd. | Immunotherapy for hepatocellular carcinoma |
| US11377449B2 (en) | 2017-08-12 | 2022-07-05 | Beigene, Ltd. | BTK inhibitors with improved dual selectivity |
| CN107722016A (zh) * | 2017-10-20 | 2018-02-23 | 尚科生物医药（上海）有限公司 | 一种无定型依鲁替尼的制备方法 |
| TW201922256A (zh) | 2017-10-27 | 2019-06-16 | 中國大陸商浙江導明醫藥科技有限公司 | 治療淋巴樣惡性疾病之方法 |
| CN111801334B (zh) | 2017-11-29 | 2023-06-09 | 百济神州瑞士有限责任公司 | 使用包含btk抑制剂的组合治疗惰性或侵袭性b-细胞淋巴瘤 |
| IL294511A (en) | 2020-01-08 | 2022-09-01 | Principia Biopharma Inc | Crystal forms of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)- 1h-pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]- 4,4-dimethylpent-2-enenitrile |
| TW202142237A (zh) | 2020-01-08 | 2021-11-16 | 美商普林斯匹亞生物製藥公司 | 包含2-[3-[4-胺基-3-(2-氟-4-苯氧基-苯基)-1h-吡唑并[3,4-d]嘧啶-1-基]哌啶-1-羰基]-4,4-二甲基戊-2-烯腈之局部醫藥組成物 |
| TW202206076A (zh) | 2020-04-22 | 2022-02-16 | 美商普林斯匹亞生物製藥公司 | 使用ｂｔｋ抑制劑對急性呼吸窘迫症候群和其他涉及細胞激素風暴的病症之治療 |
| CN111481671A (zh) * | 2020-05-26 | 2020-08-04 | 华中科技大学同济医学院附属协和医院 | 酪氨酸激酶抑制剂在制备***性红斑狼疮脑病药物中的应用 |
| US20240100172A1 (en) | 2020-12-21 | 2024-03-28 | Hangzhou Jijing Pharmaceutical Technology Limited | Methods and compounds for targeted autophagy |
| WO2022137240A1 (en) * | 2020-12-23 | 2022-06-30 | Yeda Research And Development Co. Ltd. | Methacrylamides protein binders and uses thereof |
| CN117279641A (zh) | 2021-04-16 | 2023-12-22 | 普林斯匹亚生物制药公司 | 通过施用特定化合物治疗药物和疫苗诱导的免疫性血小板减少症的方法 |
| US11786531B1 (en) | 2022-06-08 | 2023-10-17 | Beigene Switzerland Gmbh | Methods of treating B-cell proliferative disorder |
| WO2023249980A1 (en) * | 2022-06-22 | 2023-12-28 | Genzyme Corporation | Methods of making modified btk inhibitors |
Family Cites Families (84)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS428308Y1 (pl) | 1964-09-09 | 1967-04-27 | ||
| US4107288A (en) | 1974-09-18 | 1978-08-15 | Pharmaceutical Society Of Victoria | Injectable compositions, nanoparticles useful therein, and process of manufacturing same |
| JPS5617367A (en) | 1979-07-23 | 1981-02-19 | Fuji Xerox Co Ltd | Magnetic brush developing unit |
| JPS5663950A (en) | 1979-10-30 | 1981-05-30 | Mitsubishi Chem Ind Ltd | Cyclopropanecarboxylic ester |
| FR2535721A1 (fr) | 1982-11-08 | 1984-05-11 | Sanofi Sa | Derives de la piperidinedione protecteurs du myocarde presentant une acticite antiarythmique, leur procede de preparation et les medicaments qui contiennent lesdits derives |
| US4911920A (en) | 1986-07-30 | 1990-03-27 | Alcon Laboratories, Inc. | Sustained release, comfort formulation for glaucoma therapy |
| FR2588189B1 (fr) | 1985-10-03 | 1988-12-02 | Merck Sharp & Dohme | Composition pharmaceutique de type a transition de phase liquide-gel |
| CA2018801C (en) | 1990-06-12 | 2000-08-22 | Pierre Louis Beaulieu | Antiherpes peptide derivatives having a 1,4-dioxo c n-terminus |
| JPH04177244A (ja) | 1990-11-10 | 1992-06-24 | Konica Corp | ハロゲン化銀写真感光材料 |
| CA2033447C (en) | 1990-12-31 | 1999-08-31 | Robert Deziel | Synergistic combination for treating herpes infections |
| EP0495421B1 (en) | 1991-01-15 | 1996-08-21 | Alcon Laboratories, Inc. | Use of carrageenans in topical ophthalmic compositions |
| US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
| US5212162A (en) | 1991-03-27 | 1993-05-18 | Alcon Laboratories, Inc. | Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions |
| JPH05301838A (ja) | 1991-10-15 | 1993-11-16 | Mitsubishi Kasei Corp | スチレン誘導体 |
| US5792771A (en) | 1992-11-13 | 1998-08-11 | Sugen, Inc. | Quinazoline compounds and compositions thereof for the treatment of disease |
| WO1995024190A2 (en) | 1994-03-07 | 1995-09-14 | Sugen, Inc. | Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof |
| JPH0827090A (ja) | 1994-05-13 | 1996-01-30 | Sumitomo Chem Co Ltd | シアノ酢酸アミド誘導体、その用途およびその製造中間体 |
| HUP0001603A3 (en) | 1997-03-14 | 2004-05-28 | Basf Ag | Cycloalkylalkanecarboxamides and the production and use thereof |
| US7863444B2 (en) | 1997-03-19 | 2011-01-04 | Abbott Laboratories | 4-aminopyrrolopyrimidines as kinase inhibitors |
| IL125947A0 (en) | 1997-09-17 | 1999-04-11 | American Cyanamid Co | 3-(1,2-benzisothiazol- and isoxazol-5-yl)-2,4(1h,3h)-pyrimidinedione or thione and 3-(1,2-benzisothiazol- and isoxazol-5-yl)-4(3)-pyrimidinone or thione herbicidal agents |
| US6713474B2 (en) | 1998-09-18 | 2004-03-30 | Abbott Gmbh & Co. Kg | Pyrrolopyrimidines as therapeutic agents |
| CN1390219A (zh) | 1999-09-17 | 2003-01-08 | 艾博特股份有限两合公司 | 作为治疗剂的吡唑并嘧啶类 |
| IL151480A0 (en) * | 2000-03-06 | 2003-04-10 | Warner Lambert Co | 5-alkylpyrido[2,3-d] pyrimidines tyrosine kinase inhibitors |
| WO2001072751A1 (en) | 2000-03-29 | 2001-10-04 | Knoll Gesellschaft Mit Beschraenkter Haftung | Pyrrolopyrimidines as tyrosine kinase inhibitors |
| JP3991812B2 (ja) | 2001-12-11 | 2007-10-17 | 住友化学株式会社 | エステル化合物およびその用途 |
| AU2003210983A1 (en) * | 2002-02-11 | 2003-09-04 | The Brigham And Women's Hospital, Inc. | Kinase inhibitors and methods of use thereof |
| NI200300043A (es) | 2002-03-28 | 2003-11-05 | Warner Lambert Co | AMINOACIDOS CON AFINIDAD POR LA PROTEINA a2DELTA. |
| GB0219024D0 (en) | 2002-08-15 | 2002-09-25 | Pfizer Ltd | Synergistic combinations |
| US7419981B2 (en) | 2002-08-15 | 2008-09-02 | Pfizer Inc. | Synergistic combinations of an alpha-2-delta ligand and a cGMP phosphodieterse 5 inhibitor |
| GB0226370D0 (en) | 2002-11-12 | 2002-12-18 | Novartis Ag | Organic compounds |
| CA2516234A1 (en) | 2003-02-21 | 2004-09-02 | Pfizer Inc. | N-heterocyclyl-substituted amino-thiazole derivatives as protein kinase inhibitors |
| US20050008640A1 (en) | 2003-04-23 | 2005-01-13 | Wendy Waegell | Method of treating transplant rejection |
| NZ542097A (en) * | 2003-04-29 | 2008-12-24 | Pfizer Ltd | 5,7-Diaminopyrazolo[4,3-d]pyrimidines useful in the treatment of hypertension |
| ES2295930T3 (es) | 2003-08-01 | 2008-04-16 | Chugai Seiyaku Kabushiki Kaisha | Compuestos de cianoamida utiles como inhibidores de malonil-coa descarboxilasa. |
| WO2005023773A1 (en) | 2003-09-04 | 2005-03-17 | Pfizer Limited | Process for the preparation of substituted aryl pyrazoles |
| GB0322140D0 (en) | 2003-09-22 | 2003-10-22 | Pfizer Ltd | Combinations |
| KR100774625B1 (ko) | 2003-09-25 | 2007-11-08 | 워너-램버트 캄파니 엘엘씨 | 치료제 베타 아미노산 |
| WO2005074603A2 (en) | 2004-02-03 | 2005-08-18 | Abbott Laboratories | Aminobenzoxazoles as therapeutic agents |
| JP4552456B2 (ja) | 2004-02-27 | 2010-09-29 | 住友化学株式会社 | エステル化合物およびその用途 |
| JP2007523936A (ja) * | 2004-02-27 | 2007-08-23 | エフ．ホフマン−ラ ロシュ アーゲー | ヘテロアリール縮合ピラゾロ誘導体 |
| EP1724264A1 (en) | 2004-03-10 | 2006-11-22 | Ono Pharmaceutical Co., Ltd. | Nitriles and medicinal compositions containing the same as the active ingredient |
| US7807719B2 (en) | 2004-09-14 | 2010-10-05 | Chaim Roifman | Compounds useful for modulating abnormal cell proliferation |
| US20080146643A1 (en) | 2005-06-15 | 2008-06-19 | Pfizer Limited | Combination |
| US7645786B2 (en) | 2005-06-15 | 2010-01-12 | Pfizer Inc. | Substituted arylpyrazoles |
| US20070149464A1 (en) | 2005-06-15 | 2007-06-28 | Pfizer Inc. | Combination |
| US20080176865A1 (en) | 2005-06-15 | 2008-07-24 | Pfizer Limited | Substituted arylpyrazoles |
| WO2006134468A1 (en) | 2005-06-15 | 2006-12-21 | Pfizer Limited | Substituted arylpyrazoles for use against parasitites |
| CA2623327A1 (en) | 2005-10-07 | 2007-04-19 | Kissei Pharmaceutical Co., Ltd. | Nitrogenated heterocyclic compound and pharmaceutical composition comprising the same |
| EP1957078B1 (en) | 2005-12-02 | 2013-08-28 | Bayer HealthCare, LLC | Pyrrolotriazine derivatives useful for treating cancer through inhibition of aurora kinase |
| CN101421269A (zh) | 2006-01-13 | 2009-04-29 | 环状药物公司 | 酪氨酸激酶抑制剂及其用途 |
| EP2007714A2 (en) | 2006-03-31 | 2008-12-31 | The Board of Regents of The University of Texas System | Orally bioavailable caffeic acid related anticancer drugs |
| US7645748B2 (en) | 2006-04-03 | 2010-01-12 | Forbes Medi-Tech Inc. | Sterol/stanol phosphorylnitroderivatives and use thereof |
| US20100292229A1 (en) | 2006-06-30 | 2010-11-18 | The Board Of Regents Of The University Of Texas System | Tryphostin-analogs for the treatment of cell proliferative diseases |
| SI2526934T1 (sl) * | 2006-09-22 | 2016-04-29 | Pharmacyclics Llc | Inhibitorji Bruton tirozin kinaze |
| WO2008054827A2 (en) | 2006-11-03 | 2008-05-08 | Pharmacyclics, Inc. | Bruton's tyrosine kinase activity probe and method of using |
| BRPI0718948A2 (pt) | 2006-11-23 | 2013-12-17 | Novartis Ag | Pirimidinas e seu uso como antagonistas de receptores de cxcr2 |
| WO2008116064A2 (en) * | 2007-03-21 | 2008-09-25 | Bristol-Myers Squibb Company | Fused heterocyclic compounds useful for the treatment of proliferative, allergic, autoimmune or inflammatory diseases |
| GB2447933A (en) | 2007-03-27 | 2008-10-01 | Chemence Ltd | Cyanoacrylate monomer for forming an adhesive polymer |
| EP2561875A3 (en) | 2007-03-28 | 2013-06-12 | Pharmacyclics, Inc. | Inhibitors of bruton's tyrosine kinase |
| AU2009270856B2 (en) * | 2008-07-16 | 2013-07-25 | Pharmacyclics Llc | Inhibitors of Bruton's tyrosine kinase for the treatment of solid tumors |
| US20120028981A1 (en) | 2008-11-05 | 2012-02-02 | Principia Biopharma Inc. | Kinase Knockdown Via Electrophilically Enhanced Inhibitors |
| US20100113520A1 (en) | 2008-11-05 | 2010-05-06 | Principia Biopharma, Inc. | Kinase knockdown via electrophilically enhanced inhibitors |
| US8426428B2 (en) | 2008-12-05 | 2013-04-23 | Principia Biopharma, Inc. | EGFR kinase knockdown via electrophilically enhanced inhibitors |
| US7718662B1 (en) | 2009-10-12 | 2010-05-18 | Pharmacyclics, Inc. | Pyrazolo-pyrimidine inhibitors of bruton's tyrosine kinase |
| JP2013510886A (ja) | 2009-11-16 | 2013-03-28 | ザ・リージエンツ・オブ・ザ・ユニバーシテイ・オブ・カリフオルニア | キナーゼ阻害剤 |
| TWI535716B (zh) | 2010-05-31 | 2016-06-01 | Ono Pharmaceutical Co | Purine ketone derivatives |
| MX342405B (es) | 2010-06-03 | 2016-09-28 | Pharmacyclics Inc | El uso de inhibidores de la tirosina quinasa de bruton (btk). |
| CN101880243A (zh) | 2010-06-04 | 2010-11-10 | 贵阳柏丝特化工有限公司 | 一种含氟氰拟除虫菊酯化合物及其合成方法与用途 |
| WO2012158795A1 (en) | 2011-05-17 | 2012-11-22 | Principia Biopharma Inc. | Pyrazolopyrimidine derivatives as tyrosine kinase inhibitors |
| US9580427B2 (en) * | 2011-05-17 | 2017-02-28 | The Regents Of The University Of California | Kinase inhibitors |
| WO2012158810A1 (en) | 2011-05-17 | 2012-11-22 | Principia Biopharma Inc. | Tyrosine kinase inhibitors |
| US8962831B2 (en) | 2011-05-17 | 2015-02-24 | Principia Biopharma Inc. | Tyrosine kinase inhibitors |
| WO2013003629A2 (en) | 2011-06-28 | 2013-01-03 | Pharmacyclics, Inc. | Methods and compositions for inhibition of bone resorption |
| BR112014000653A2 (pt) | 2011-07-13 | 2017-02-14 | Pharmacyclics Inc | inibidores de tirosina quinase de bruton |
| EP2548877A1 (en) | 2011-07-19 | 2013-01-23 | MSD Oss B.V. | 4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors |
| JP2014522860A (ja) | 2011-07-19 | 2014-09-08 | メルク・シャープ・アンド・ドーム・ベー・フェー | Ｂｔｋ阻害剤としての４−イミダゾピリダジン−１−イル−ベンズアミドおよび４−イミダゾトリアジン−１−イル−ベンズアミド |
| DK2734522T3 (en) | 2011-07-19 | 2019-02-18 | Merck Sharp & Dohme | 4-IMIDAZOPYRIDAZIN-1-YL-BENZAMIDES AND 4-IMIDAZOTRIAZIN-1-YL-BENZAMIDES AS BTK INHIBITORS |
| JP6506555B2 (ja) | 2011-10-19 | 2019-04-24 | ファーマサイクリックス エルエルシー | ブルトン型チロシンキナーゼ（Ｂｔｋ）阻害剤の使用 |
| US8377946B1 (en) | 2011-12-30 | 2013-02-19 | Pharmacyclics, Inc. | Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors |
| US8501724B1 (en) | 2012-01-31 | 2013-08-06 | Pharmacyclics, Inc. | Purinone compounds as kinase inhibitors |
| MX368112B (es) | 2012-06-18 | 2019-09-18 | Principia Biopharma Inc | Pirrolo- o pirazolopirimidinas covalentes reversibles utiles para el tratamiento del cancer y de enfermedades autoinmunitarias. |
| US9572811B2 (en) | 2012-08-03 | 2017-02-21 | Principia Biopharma Inc. | Treatment of dry eye |
| PE20151495A1 (es) | 2012-11-15 | 2015-10-23 | Pharmacyclics Inc | Compuestos de pirrolopirimidina como inhibidores de quinasas |
| US20140142099A1 (en) | 2012-11-20 | 2014-05-22 | Principia Biopharma Inc. | Purinone Derivatives as Tyrosine Kinase Inhibitors |
-
2012
- 2012-05-16 US US14/117,933 patent/US8962831B2/en active Active
- 2012-05-16 HU HUE12722662A patent/HUE033019T2/en unknown
- 2012-05-16 MX MX2013013294A patent/MX347040B/es active IP Right Grant
- 2012-05-16 SI SI201230743A patent/SI2710005T1/sl unknown
- 2012-05-16 EP EP12722662.9A patent/EP2710005B1/en active Active
- 2012-05-16 CN CN201280023262.9A patent/CN103534258B/zh active Active
- 2012-05-16 KR KR1020137033089A patent/KR102027598B1/ko active IP Right Grant
- 2012-05-16 CA CA2836410A patent/CA2836410C/en active Active
- 2012-05-16 AU AU2012255860A patent/AU2012255860C1/en active Active
- 2012-05-16 JP JP2014511480A patent/JP5974084B2/ja active Active
- 2012-05-16 ES ES12722662.9T patent/ES2604191T3/es active Active
- 2012-05-16 PT PT127226629T patent/PT2710005T/pt unknown
- 2012-05-16 EA EA201391528A patent/EA025496B1/ru not_active IP Right Cessation
- 2012-05-16 PL PL12722662T patent/PL2710005T3/pl unknown
- 2012-05-16 WO PCT/US2012/038092 patent/WO2012158764A1/en active Application Filing
-
2015
- 2015-01-06 US US14/590,851 patent/US20150353557A1/en not_active Abandoned
- 2015-10-19 AU AU2015243110A patent/AU2015243110B2/en active Active
-
2017
- 2017-01-05 HR HRP20170017TT patent/HRP20170017T1/hr unknown
-
2018
- 2018-07-26 AU AU2018208715A patent/AU2018208715A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| PT2710005T (pt) | 2016-11-16 |
| ES2604191T3 (es) | 2017-03-03 |
| AU2012255860A1 (en) | 2013-04-18 |
| CN103534258B (zh) | 2016-09-14 |
| AU2015243110B2 (en) | 2018-05-24 |
| AU2012255860C1 (en) | 2015-12-10 |
| HRP20170017T1 (hr) | 2017-02-24 |
| CA2836410A1 (en) | 2012-11-22 |
| AU2012255860B2 (en) | 2015-07-23 |
| BR112013028846A2 (pt) | 2020-01-21 |
| EA201391528A1 (ru) | 2014-09-30 |
| SI2710005T1 (sl) | 2017-03-31 |
| US20140094459A1 (en) | 2014-04-03 |
| US20150353557A1 (en) | 2015-12-10 |
| EP2710005A1 (en) | 2014-03-26 |
| KR20140058438A (ko) | 2014-05-14 |
| JP2014517838A (ja) | 2014-07-24 |
| MX2013013294A (es) | 2014-04-25 |
| JP5974084B2 (ja) | 2016-08-23 |
| EA025496B1 (ru) | 2016-12-30 |
| AU2018208715A1 (en) | 2018-08-16 |
| WO2012158764A1 (en) | 2012-11-22 |
| AU2015243110A1 (en) | 2015-11-05 |
| EP2710005B1 (en) | 2016-10-05 |
| CN103534258A (zh) | 2014-01-22 |
| US8962831B2 (en) | 2015-02-24 |
| HUE033019T2 (en) | 2017-11-28 |
| KR102027598B1 (ko) | 2019-10-01 |
| MX347040B (es) | 2017-04-10 |
| CA2836410C (en) | 2019-08-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT2710005T (pt) | Inibidores de tirosina-quinase | |
| HK1200828A1 (en) | Kinase inhibitors | |
| HK1200451A1 (zh) | 蛋白激酶抑制劑 | |
| HUE048834T2 (hu) | Kináz inhibitorok | |
| EP2694517A4 (en) | PROTEIN KINASE INHIBITORS | |
| EP2552208A4 (en) | IMIDAZOLYL-IMIDAZOLES AS KINASE INHIBITORS | |
| IL228103A0 (en) | Amino-quinolines as kinase inhibitors | |
| EP2552211A4 (en) | INDAZOLYL-PYRIMIDINE AS KINASEHEMMER | |
| ZA201306855B (en) | Protein kinase inhibitors | |
| IL229028A0 (en) | Kinase inhibitors | |
| GB201009731D0 (en) | Kinase inhibitors | |
| HK1199873A1 (en) | Kinase inhibitors | |
| EP2685992A4 (en) | AMINO-QUINOLINES AS KINASE INHIBITORS | |
| IL232234A0 (en) | Inhibitors of aminopyrimidine kinase | |
| IL228928A0 (en) | Aminopyrimidine kinase inhibitors | |
| GB201114851D0 (en) | Novel lim kinase inhibitors |